Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Irinotecan and Bevacizumab Without Panitumumab	115
Overall Study	STARTED	Oxaliplatin and Bevacizumab Plus Panitumumab	413
Overall Study	STARTED	Oxaliplatin and Bevacizumab Without Panitumumab	410
Overall Study	STARTED	Irinotecan and Bevacizumab Plus Panitumumab	115
Overall Study	COMPLETED	Irinotecan and Bevacizumab Without Panitumumab	80
Overall Study	COMPLETED	Oxaliplatin and Bevacizumab Plus Panitumumab	313
Overall Study	COMPLETED	Oxaliplatin and Bevacizumab Without Panitumumab	289
Overall Study	COMPLETED	Irinotecan and Bevacizumab Plus Panitumumab	84
Overall Study	NOT COMPLETED	Irinotecan and Bevacizumab Without Panitumumab	35
Overall Study	NOT COMPLETED	Oxaliplatin and Bevacizumab Plus Panitumumab	100
Overall Study	NOT COMPLETED	Oxaliplatin and Bevacizumab Without Panitumumab	121
Overall Study	NOT COMPLETED	Irinotecan and Bevacizumab Plus Panitumumab	31

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00115765/flow